<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJMI</journal-id><journal-title-group><journal-title>Open Journal of Medical Imaging</journal-title></journal-title-group><issn pub-type="epub">2164-2788</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojmi.2014.44023</article-id><article-id pub-id-type="publisher-id">OJMI-51442</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Cranial Magnetic Resonance Spectroscopy: An Update of Metabolites and a Special Emphasis on Practical Points
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>uzgun</surname><given-names>Yildirim</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Onur</surname><given-names>Tutar</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Deniz</surname><given-names>Alis</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gokhan</surname><given-names>Kuyumcu</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Selim</surname><given-names>Bakan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Centermed Advanced Imaging Center, Istanbul, Turkey</addr-line></aff><aff id="aff2"><addr-line>Depatment of Radiology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>yildirimduzgun@yahoo.com(UY)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>11</month><year>2014</year></pub-date><volume>04</volume><issue>04</issue><fpage>163</fpage><lpage>171</lpage><history><date date-type="received"><day>8</day>	<month>September</month>	<year>2014</year></date><date date-type="rev-recd"><day>8</day>	<month>October</month>	<year>2014</year>	</date><date date-type="accepted"><day>7</day>	<month>November</month>	<year>2014</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Magnetic resonance spectroscopy (MRS) could be used for dozens of metabolites [1]. In this paper we will focus especially on proton (hydrogen) MRS. Generally published literatures consist of reviews and articles about metabolites are long, complicated and emphasise on physical or on technical data. But with this article, we will try to explain basically how MRS could be used in daily practice of radiologists. First of all we tried to search all current literature only referencing the main ones to make this review and we want all of our colleagues to give feedback about this review. With collection of all these trick points and line up to appropriate order, it is possible to make this review a common guide for radiologists and a useful tool while reporting MRS.
 
</p></abstract><kwd-group><kwd>Magnetic Resonance Spectroscopy</kwd><kwd> Analysis</kwd><kwd> Metabolite Markers</kwd><kwd> Radiology</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction, Technique and Short Tips on Protocol</title><p>After the 3 tesla MRS came into use, we are able to measure main metabolites more accurately, also with current softwares we are able to measure more metabolites. So with all those new developments, differential diagnosis of metabolical diseases, follow up of demyelinating diseases, differentiation of malignant and benign tumours and staging of tumours are much easier. The most important part of MRS is, it has ability to measure chemical component of the area that we study, non invasively (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>Generally metabolites are distributed between water and lipid peaks. There are different techniques to obtain metabolite information but this is not a subject for this review. But at least we can say that there are mainly two</p><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> An example of MRS study on workstation: in MRS examination, with showing reference images and peak values of metabolites, we could differentiate tumour necrosis, recurrence and infiltration from each other. In high grade glioma case control after radiotherapy; a) High Cho/NAA ratios at the centre of lesion; b) decreased values at periphery c) contrast administered T1 axial images showed heterogeneous signal enhancement at post-radiotherapy area; d) Color map of metabolites and e) with superposed of peak metabolite information we showed there is only small malign transformation zone at the center of the area within the examined voxel of interest</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/1-2060127x5.png"/></fig><p>methods in use and with PRESS (point resolved spectroscopy) method signal-noise ratio is higher [<xref ref-type="bibr" rid="scirp.51442-ref2">2</xref>] . In STEAM (stimulated echo acquisition mode) method we could work with shorter TE values and we could get more detailed table of metabolites [<xref ref-type="bibr" rid="scirp.51442-ref3">3</xref>] .</p><p>During examination, voxel of interest should not include especially scalp, sinuses, air or haemorrhagic foci. Normal CSF may dilute concentration but does not cause significant degradation of spectrum content. Also jewellery and ventriculoperitoneal shunts could disturb optimal settings of shimming and could change spectrum. Gadolinium could decrease the cho peak by % 12 - 15, because of that MRS should be done before administration of contrast material. Because there is no certain normal international reference values for MRS metabolites, measurements could be compared with examined cases’ own normal and abnormal regions. Also, some determined ratios of well known ratios can help in differential diagnosis as defined in <xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="table" rid="table2">Table 2</xref>.</p><p>On starting to examination, single or multi voxel protocol must be selected considering the purpose of the study. In searching of brain tumour which has got a heterogeneous or infiltrative pattern we should use multi-voxel protocol [<xref ref-type="bibr" rid="scirp.51442-ref4">4</xref>] . But in small lesions, posterior fossa tumors, or if there is a non removable metallic implant near the VOI, we should use single voxel protocol [<xref ref-type="bibr" rid="scirp.51442-ref1">1</xref>] . Especially for searching metabolic diseases, to achieve resonances of minor metabolites short TE values must be selected. Distribution of metabolites in resonance spectrum peaks could change due to: the device we use, the power of magnetic field. Also, shimming parameters can lead to different ppm values thorough the baseline but these changes are minor and do not cause significant diagnostic difficulties. In short TE examinations, Cr shows faster decay then other metabolites cause of that Cho/Cr ratio is higher at short examinations [<xref ref-type="bibr" rid="scirp.51442-ref5">5</xref>] .</p><p>In grey matter NAA, Cr and glx are higher quantities, but in white matter Cho is relatively high [<xref ref-type="bibr" rid="scirp.51442-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.51442-ref7">7</xref>] Both hemispheres nearly have the same amount of metabolites but from occipital to frontal direction Cho decreases little bit. In basal ganglia, NAA and myo-inositol decrease. In pons, Cho and Cr are high but NAA and myo-in- ositol are low. In cerebellum, Cho and Cr are high but NAA is low [<xref ref-type="bibr" rid="scirp.51442-ref8">8</xref>] .</p></sec><sec id="s2"><title>2. Metabolites</title><p>NAA is the major neuronal metabolite and Cho, Cr, mIns, glutamate are the other ones. Whereas, the brain normally doesn’t include high quantity of some metabolites (like lactate, hydroxy butyrate, acetone, glycine, succinate, pyruvate, alanine, lipid, phenylalanine, mannitol, ethanol, etc.) to definable on normal resonance line.</p><p>Diagnosis could be made by determining such abnormal metabolites or with determining changes of normal metabolites. Also with using a special technique, NAA’s amid component’s changes could be determined by administering histidine and homocarnosine. And so, brain PH levels could be measured by determination of NAA level changes. Also with whole brain spectroscopy, quantitative values of all metabolites could be measured.</p><p>Different components of metabolites could be useful for defining the different peak values of the same product. For example: NAA 2.02 and 2.6 ppm, Cr at 3.02 and 3.9 ppm, Glx between 2.05 - 2.4 and 3.65 - 3.8 ppm, glucose at 3.43 and 3.48 ppm, myo-inositol between 3.56 and 4.06. But, generally, only the established dominant ones to be considered for diagnosis.</p><p>Main metabolites: Cho (choline, 3.2 ppm), Cr (creatine, 3.0 ppm), NAA (n-acetile aspartic acid, 2.02 ppm), Mi (myo-inositole, 3.56 ppm) Lip (Lipid, 0.8 - 1.5 ppm), Lac ( lactate, 1.3 ppm) . The other metabolites will be explained later by shortly. Water peak visualised at 4.7 ppm and it is used as reference value. All these metabolites that rises before water peak could be identified by spectral editing.</p><p>Cho: Marker of membrane proliferation, above normal values usually gives warning about malignity [<xref ref-type="bibr" rid="scirp.51442-ref9">9</xref>] .</p><p>Cr: Peaks at 3.2 ppm. Useful as an internal reference [<xref ref-type="bibr" rid="scirp.51442-ref10">10</xref>] .</p><p>NAA: Neuronal marker. The only situation causes increased NAA is Canavan disease. Generally all other diseases cause reduced NAA levels [<xref ref-type="bibr" rid="scirp.51442-ref11">11</xref>] .</p><p>mI: As a glial proliferation marker, it increases in diabetes, Alzheimer disease, PMLE, Down syndrome; and decreases in stroke, tumours and encephalopathies. While mI is increases in Alzheimer and Down syndrome, it decreases in other cases of dementia [<xref ref-type="bibr" rid="scirp.51442-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.51442-ref13">13</xref>] .</p><p>mI and glycine’s peak values are so close to each other, they both resonate at 3.5 - 3.6 ppms (gly: 3.55-singlet, mIns: 3.52 - 3.61-multiplet). Myo-inositol makes multiplet at short TE’s. It’s strength decreases at long TE values. Contrary to this, glycine resonates as a singlet peak and its visualisation enhances at long TE values. Gly increases in stroke, encephalitis, Huntington, Parkinson, Alzheimer and Van der Knaap diseases [<xref ref-type="bibr" rid="scirp.51442-ref14">14</xref>] .</p><p>In infantile periods, mI is the dominant peak at first months and Cho is also high at these times. But then mI’s and Cho’s peak values decreases as NAA, Cr increases. After the end of age 2, MRS patterns of metabolites becomes similar with adult level [<xref ref-type="bibr" rid="scirp.51442-ref15">15</xref>] .</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Example of normal metabolite ratios for children and adults</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Normal</th><th align="center" valign="middle" >Neonatal</th><th align="center" valign="middle" >Infantile</th><th align="center" valign="middle" >Child</th><th align="center" valign="middle" >Adult</th></tr></thead><tr><td align="center" valign="middle" >NAA/Cho</td><td align="center" valign="middle" >0.67 &#177; 0.17</td><td align="center" valign="middle" >1.56 &#177; 0.67</td><td align="center" valign="middle" >3.43 &#177; 1.04</td><td align="center" valign="middle" >2.37 &#177; 0.40</td></tr><tr><td align="center" valign="middle" >Cho/Cr</td><td align="center" valign="middle" >1.27 &#177; 0.40</td><td align="center" valign="middle" >0.84 &#177; 0.21</td><td align="center" valign="middle" >0.49 &#177; 0.16</td><td align="center" valign="middle" >1.05 &#177; 0.23</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Example of metabolite ratios for differentiation of low and high grade glial tumors</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Normal</th><th align="center" valign="middle" >NAA/Cr = 1.5 &#177; 0.2</th><th align="center" valign="middle" >Cho/Cr = 1.05 &#177; 0.23</th><th align="center" valign="middle" >NAA/Cho = 2.37 &#177; 0.40</th></tr></thead><tr><td align="center" valign="middle" >Gliom low grade</td><td align="center" valign="middle" >NAA/Cr = 1.12 &#177; 0.48</td><td align="center" valign="middle" >Cho/Cr = 1.71 &#177; 0.63</td><td align="center" valign="middle" >NAA/Cho = 0.65 &#177; 0.37</td></tr><tr><td align="center" valign="middle" >Gliom high grade</td><td align="center" valign="middle" >NAA/Cr = 0.66 &#177; 0.37</td><td align="center" valign="middle" >Cho/Cr = 1.95 &#177; 0.72</td><td align="center" valign="middle" >NAA/Cho = 0.33 &#177; 0.17</td></tr></tbody></table></table-wrap><p>Glutamate/glutamine: Some times these couple of metabolites are called as Glx. Glx peaks mainly between 2.1 and 2.45. In MS plaques, hepatic encephalopathy, and Reyes syndrome, increased ammonia level causes increase in Glx peak values [<xref ref-type="bibr" rid="scirp.51442-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.51442-ref17">17</xref>] .</p><p>GABA: It is visualised at 1.9, 2.3, 3.0 ppm’s, but 2.3 ppm should be first choice because at 1.9 and 3.0 ppm values it overlaps by other dominant metabolites. Simply, for GABA 2.31 ppm and for Glutamine 2.62 pm values could be used. As a new method, MegaPRESS sequence could be used for quantitative differentiation of GABA [<xref ref-type="bibr" rid="scirp.51442-ref18">18</xref>] .</p><p>Lactate (resonates at 1.3 ppm) is more prominent at longs TE values. In 1.5 tesla 150 ms, in 3 tesla 140 ms is the most suitable values. Inversion of lactate at short TE values could be incomplete at 3 Tesla systems. But generally, in shorts TE’s lactate is inverted but lipid is more prominent.</p><p>2-Hydroxyglutarate: gioma cases that have isocitrate dehydrogenase mutations. So, 2-hydroxyglutarate increases and visualised especially with TE: 90 - 100 ms at 2.25 ppm. Glioma cases that have high rate of this metabolite have good response to angiogenic therapy [<xref ref-type="bibr" rid="scirp.51442-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.51442-ref20">20</xref>] .</p><p>Lipid-macromolecular peaks resonates at 0.8, 1.2 1.5, 6.0 ppms. 0.8 - 1.2 ppm values usually called as lipid-macromolecular non-specific peak. If there is too much lipid we should use long TE for decrease lipids that have shorter TE values to get clear resonance graphics (It increases in tumours, metastasis and post-radiotherapy changes) [<xref ref-type="bibr" rid="scirp.51442-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.51442-ref21">21</xref>] .</p><p>Pyruvate: it peaks at 2.37 ppm. Normally couldn't detected but increase and could be defined in pyruvate dehydrogenase enzyme deficiency [<xref ref-type="bibr" rid="scirp.51442-ref22">22</xref>] .</p><p>Syllo-inositole: peaks at 3.35 ppm, increases in alcoholism and glioneuronal tumours. It can be rise in early infancy especially at examinations obtained in 3 Tesla systems. It can be superposed by taurine but taurine has simple peak while sylloinositole has a more complex one [<xref ref-type="bibr" rid="scirp.51442-ref23">23</xref>] .</p><p>Guanidinoacetate: Increases at 3.78 ppm. It is lower in anaplastic astrocytomas then other gliomas [<xref ref-type="bibr" rid="scirp.51442-ref24">24</xref>] .</p><p>Citrate: Increases at 2.6 ppm in some brain tumours like PNET and high grade glial tumours [<xref ref-type="bibr" rid="scirp.51442-ref25">25</xref>] .</p><p>Melanin: Peaks at 6.72 ppm. It can be detected in lesions that contain melanin.</p><p>Glucose: Peaks at 3.43 and 3.80 ppm. Increases in DM and hyperglycemia crisis.</p><p>Glutathione: Detected at 2.95 ppm. Increases in GBM, meningioma, and ischemic oxidative stress.</p><p>Additional to searching all these metabolites on resonance line, also there are some useful metabolite ratios to increase the strength of differential diagnosis (<xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="table" rid="table2">Table 2</xref>).</p><p>It’s very hard to keep all those values defined on <xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="table" rid="table2">Table 2</xref> in mind so we should check on tables when we need to. But with practical approach we can use these following simplified ratios especially when searching for gliomas.</p><p>NORMAL: NAA/Cr &gt; 2.0, NAA/Cho &gt; 1.6, Cho/Cr &lt; 1.2</p><p>ABNORMAL: NAA/Cr &lt; 1.6, NAA/Cho &lt; 1.2, Cho/Cr &gt; 1.5</p><p>Generally, instead of using MRS alone, we should use other conventional and multi parametric methods together for diagnosis. For example in high grade tumours; Cho and rCBV is high, in low grade tumours myo-in- ositol and glycine is high but rCBV is low. In PNET, Cho is high but NAA is low and taurine can also be high.</p><sec id="s2_1"><title>2.1. Special Clues for Specific Diseases</title><sec id="s2_1_1"><title>2.1.1. Craniopharyngioma</title><p>MRS establishes high levels of lipid and lactate due to rich cholesterol crystals and lipid deposits whereas normal neuronal metabolites are lower or absent. As cranial fossa base and bones are superposed and volume of hypophysis gland is lower than 2 mm, MRS is not very effective. If craniopharyngioma is large enough, especially at 1.5 ppm, it could be seen that central lipid-cholesterol peaks are high but Cho-NAA peaks are not. However, high Cho/Cr levels and presence of NAA are detected in gliomas that mimic craniopharyngioma which are located at hypothalamic or chiasmatic region [<xref ref-type="bibr" rid="scirp.51442-ref26">26</xref>] .</p></sec><sec id="s2_1_2"><title>2.1.2. Meningioma</title><p>Cytosolic amino-acides like Alanine (1.48 ppm), Acetate (1.9 ppm), Valine (0.9 ppm), Leucine (3.6 ppm) could increase. Furthermore, increase in Glx peak between 2.1 - 2.4 ppm and Glutathione peak at 2.95 have been notified in some literature. With respect to these characteristics, it is possible to distinguish schwannomas located in the same region or atypically located meningiomas (intraosseous or intraventricular) [<xref ref-type="bibr" rid="scirp.51442-ref27">27</xref>] .</p></sec><sec id="s2_1_3"><title>2.1.3. Etanol Intoxication</title><p>At 1.2 ppm, an increased triplet peak may be defined.</p></sec><sec id="s2_1_4"><title>2.1.4. Ischemia</title><p>In early phase of acute stroke NAA decreases and this decrease continues during the first week. Creatine acts similar to NAA. But choline levels are not reliable and they are variable. On the other hand, lactate level starts to increase a few minutes after stroke. It decreases again by reperfusion [<xref ref-type="bibr" rid="scirp.51442-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.51442-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.51442-ref29">29</xref>] . However although it is hard to detect at this level, penumbra that has normal NAA and high lactate levels may be detected by MRS and reperfusion can be provided and viability can be pursued [<xref ref-type="bibr" rid="scirp.51442-ref29">29</xref>] .</p></sec></sec><sec id="s2_2"><title>2.2. Hypoxic Ischemic Encephalopathy</title><p>Lac and Glu increase and NAA ratio decreases. A severe variability in Cho levels is not expected.</p><sec id="s2_2_1"><title>2.2.1. Abscess</title><p>If it is tuberculosis abscess, lipid lactate levels increase, NAA and Cho decrease and a small increase is observed in aminoacid levels [<xref ref-type="bibr" rid="scirp.51442-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.51442-ref31">31</xref>] .</p><p>In pyogenic abscess, increase of aminoacid levels are more apparent [<xref ref-type="bibr" rid="scirp.51442-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.51442-ref32">32</xref>] .</p><p>In fungal abscess, lipid lactate levels increase more then aminoacid levels. Unlike Tbc abscess, especially in angioinvasive type, the intricated walls called crenelated outlines [<xref ref-type="bibr" rid="scirp.51442-ref30">30</xref>] .</p></sec><sec id="s2_2_2"><title>2.2.2. Multiple Sclerosis</title><p>NAA decreases, Cho, lactate and myoinositol increase [<xref ref-type="bibr" rid="scirp.51442-ref33">33</xref>] [<xref ref-type="bibr" rid="scirp.51442-ref34">34</xref>] .</p></sec><sec id="s2_2_3"><title>2.2.3. Hepatic Encephalopathy</title><p>Due to increase in ammonia level, Glu peak rises. Myoinositol and Cho decrease and lactate increases [<xref ref-type="bibr" rid="scirp.51442-ref35">35</xref>] . Decrease in Cho and Cr levels, particularly at follow-up imaging indicates poor prognosis [<xref ref-type="bibr" rid="scirp.51442-ref36">36</xref>] . According to the recent studies, decrease of myoinositol can be detected even at early phase. So it is possible to establish pathology during early phase and beginning of therapy can be expedited in suspected cases.</p></sec><sec id="s2_2_4"><title>2.2.4. Epilepsy</title><p>Since the quality of spectrum is more clear and relatively more quantitative, MRS is implemented as single voxel. Multivoxel-CSI needs longer time, and since many of epilepsy patients are pediatric, they move during the process and distortion occurs in images. During acute phase, sodium/myoinositol pump increases myo-inositol levels. But the artefacts due to movements of epileptic ictus make it difficult to detect. In the interictal phase, NAA decreases due to neuronal decrement and myo-inositol shows moderate increases due to reactive astrogliosis in hypocampal sclerosis [<xref ref-type="bibr" rid="scirp.51442-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.51442-ref37">37</xref>] . In patients who take vigabatrin treatment, temporary T2 signal amplification may be seen in dentate nucleus, globus pallidus, brain stem and thalamus. In these regions, MRS is normal and is used especially to follow up signal differences due to vigabatrin. In epileptic cases MRS is used to follow up kethogenic diet. The recommended diet has low carbohydrate and high lipid [<xref ref-type="bibr" rid="scirp.51442-ref38">38</xref>] . The liver excrete ketoacides, kethon particules arising at 2 ppm, acetoasetate at 2.5 and 3.46 ppm. In epileptic cases, it is important to establish lateralisation of temporal lob which has normal signal appearance in conventional sequences but in fact generates epilepsy. NAA/Cr ratio decreases at abnormal site, but, as it is known in literature that contralateral side may show lower NAA/Cr level up to 50%, comparing both sides must be done carefully [<xref ref-type="bibr" rid="scirp.51442-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.51442-ref4">4</xref>] .</p></sec></sec><sec id="s2_3"><title>2.3. Propylene Glycol</title><p>A solvent which is used in several operations, several treatment protocols and in some drugs that are used in preoperative or intraoperative anesthesia, peaks at 1.13 ppm at MRS. This solvent also exists in several drugs and benefical in security and follow-up of the treatment.</p><sec id="s2_3_1"><title>2.3.1. RT Necrosis</title><p>At 0 - 2 ppm interval, there is lip-macromolecule peak increase that supress other peaks occur [<xref ref-type="bibr" rid="scirp.51442-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.51442-ref39">39</xref>] . Beside this giant peak, signs of neuronal viability are low.</p></sec><sec id="s2_3_2"><title>2.3.2. Psychiatric Cases</title><p>During Lithium treatment, Cho levels diminishes [<xref ref-type="bibr" rid="scirp.51442-ref40">40</xref>] . Occasionally it is useful to decide whether the drug has been used or not. For other neuropsychiatric conditions, many data from literature show some complicated and inconsistent information that could not been summarised shortly in this paper.</p></sec><sec id="s2_3_3"><title>2.3.3. Kernicterus</title><p>NAA/Cho ratio decreases, myo-inositol, taurin and Glx peaks arise [<xref ref-type="bibr" rid="scirp.51442-ref16">16</xref>] . Lactate level does not increase, so it is distinguishable from hypoxic ischemic conditions.</p></sec><sec id="s2_3_4"><title>2.3.4. Oligodendroglioma</title><p>Tumour is identifiable as; myo-inositol is very high [<xref ref-type="bibr" rid="scirp.51442-ref41">41</xref>] , Cho is very low, perfusion is highly increased and in enhancement is predominantly cortical.</p></sec><sec id="s2_3_5"><title>2.3.5. Lymphoma</title><p>In MRS, lymphoma shows abnormally high lipid-lactate ratio, ADC levels are low relatively to other lesions. rCBV ratio is generally lower than expected (&lt;2.3). In metastasis and GBM these ratio is very high. In metastasis peritumoural perfusion has not increased versus to GBM. Discrimination of diagnosis is safe based on these indirect indicators. In cerebral lymphoma, very high increase of Cho is useful to distinguish from toxoplasma, tuberculosis and cryptococcus infection [<xref ref-type="bibr" rid="scirp.51442-ref42">42</xref>] [<xref ref-type="bibr" rid="scirp.51442-ref43">43</xref>] .</p></sec></sec><sec id="s2_4"><title>2.4. Metabolic Diseases</title><p>In MSUD (maple syrupe urine disease): at 0.9 - 1.0 ppm long branched-chained amino acids, in diabetic ketoacidosis at 2.2 ppm acetone and at 3.4 ppm glucose increase.</p><p>In galactosemia: galactitol (which mimics lactose) peak between 3.67 - 3.74 ppms.</p><p>In phenylketonuria: phenylalanine peak arises at 7.6 ppm.</p><p>In lipid storage diseases: high levels of lipid resonance occur generally at 0.7 - 1.6 ppms.</p><p>Increased lactate is obvious in mitochondria storage disease as Leigh, MERF (Myoclonus epilepsy with ragged-red fibers) and MELAS (Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes).</p><p>Scyllo-inositol increases at 3.35 ppm in peroxisomal diseases.</p><p>For diagnosis and follow-up of glial tumours, especially perfusion MRI, all the imaging parameters should be used in collaboration. For example, low rCBV and high ml/Cr indicates low grade tumour whereas Cr is low and it is at least grade III GBM. These alterations are proportional to Ki-67 which is a indicator of proliferation-mi- tosis and high Cho and low Cr are indicators of poor prognosis [<xref ref-type="bibr" rid="scirp.51442-ref44">44</xref>] [<xref ref-type="bibr" rid="scirp.51442-ref45">45</xref>] . Low grade tumours may transform to high grade tumours within 5 - 10 years. As tumour grade increases, myo-inositol levels decrease.</p><p>Tumours after radiotherapy, if rCBV &gt; 1.3 we have to think relapse instead of necrosis. If rCBV &gt; 1.75, Cho/Cr &gt; 1.83 and Cho/NAA &gt; 1.92 it is acceptable as high grade. Peritumoural infiltration is possible if tissue which is surrounding lesions has Cho/Cr ratio more than 1.3 times.</p><p>Cho may have misleading elevations in pilocytic astrositoma. This is due to increase of glycerophosphocholine instead of pathologic phosphocoline. Unfortunately discrimination is not possible with MRS. Clinical situations, age and conventional sequences may help. Beside these, in pilocytic astrositoma unassigned peak elevation occurs at 2.8 ppm due to unsaturated fatty acids increase.</p><p>For differential diagnosis in such conditions, data from MRS should be used in conjunction with conventional and advanced neuroradiological findings. For example, in T2 perfusion, signal fall to 75% level is important, as line approaches to baseline at normal brain and gliomas. In lymphoma and pilocytic astrocytoma, it may arise to higher than baseline. But in meningiomas it is remote from baseline. Unlike choroid plexus papillomas, intraventricular meningiomas has rich perfusion. In choroid plexus papillomas myo-inositol is very high. As atypia and malignity progress, myo-inositol falls and Cho increases [<xref ref-type="bibr" rid="scirp.51442-ref44">44</xref>] . Though to looking intricated, we radiologists must be used to combine these rules in daily practice to solve the complex imaging findings.</p><p>As another example, in addition to MRS, ADC (apparent diffusion coefficient) values gain advantage when making diagnosis. At posterior fossa tumours, which display similar conventional findings, ADC measurement can help to differentiation. Because, ADC value is between 1.0 - 1.3 (&#215;10<sup>−3</sup> mm<sup>2</sup>/s) for ependymoma, lower than 0.7 for medulloblastoma, and generally higher than 1.4 for pilocytic astrocytoma.</p></sec></sec><sec id="s3"><title>3. Conclusion</title><p>In conclusion, with this condensed review, despite a high technical-physical burden about MRS which is highly complicated and intense, we provide much practical information. We also believe to ensure knowing basic informations from performing protocol to permutation of metabolites as well as essential data about rare metabolites and differences on spectrum made by several diseases. With development of software and hardware, utilisation of MRS in diagnostic radiology will expand beyond today.</p></sec></body><back><ref-list><title>References</title><ref id="scirp.51442-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Oz, G., Alger, J.R., Barker, P.B., Bartha, R. and Bizzi, A. (2014) MRS Consensus Group. Clinical Proton MR Spectroscopy in Central Nervous system Disorders. Radiology, 270, 658-679.  
http://dx.doi.org/10.1148/radiol.13130531</mixed-citation></ref><ref id="scirp.51442-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Burtscher, I.M. and Holtas, S. (2001) Proton MR Spectroscopy in Clinical Routine. Journal of Magnetic Resonance Imaging, 13, 560-567. http://dx.doi.org/10.1002/jmri.1079</mixed-citation></ref><ref id="scirp.51442-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Frahm, J., Merboldt, K.D. and Hanicke, W. (1969) Localised Proton Spectroscopy Using Stimulated Echoes. Journal of Magnetic Resonance, 72, 502-508.</mixed-citation></ref><ref id="scirp.51442-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Gillard, J.H., Waldman, A.D. and Barker, P.B. (2005) Clinical MR Neuroimaging. Cambridge University Press, New York.</mixed-citation></ref><ref id="scirp.51442-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Zimmerman, R.A. and Wang, Z.J. (1997) The Value of Proton MR Spectroscopy in Pediatric Metabolic Brain Disease. American Journal of Neuroradiology, 18, 1872-1879.</mixed-citation></ref><ref id="scirp.51442-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kreis, R., Ernst, T. and Ross, B.D. (1993) Absolute Quantitation of Water and Metabolites in the Human Brain. II, Metabolite Concentrations. Journal of Magnetic Resonance, Series B, 102, 9-19.  
http://dx.doi.org/10.1006/jmrb.1993.1056</mixed-citation></ref><ref id="scirp.51442-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Doyle, T.J., Bedell, B.J. and Narayana, P. (1995) Relative Concentrations of Proton MR Visible Neurochemicals in Gray and White Matter in Human Brain. Magnetic Resonance in Medicine, 33, 755-759.  
http://dx.doi.org/10.1002/mrm.1910330603</mixed-citation></ref><ref id="scirp.51442-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Soher, B.J., van Zijl, P., Duyn, J.H. and Barker, P.B. (1996) Quantitative Proton MR Spectroscopic Imaging of the Human Brain. Magnetic Resonance in Medicine, 35, 356-363. http://dx.doi.org/10.1002/mrm.1910350313</mixed-citation></ref><ref id="scirp.51442-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Maheshwari, S.R., Fatterpekar, G.M., Castillo, M. and Mukherji, S.K. (2000) Proton MR Spectroscopy of the Brain. Seminars in Ultrasound, CT and MRI, 21, 434-451. http://dx.doi.org/10.1016/S0887-2171(00)90036-2</mixed-citation></ref><ref id="scirp.51442-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Danielsen, E.R., Ross, B. and Danielsen, E.R. (1999) Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases. Marcel Dekker, New York, 30-34.</mixed-citation></ref><ref id="scirp.51442-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Castillo, M., Kwock, L., Scatliff, J. and Mukherji, S.K. (1998) Proton MR Spectroscopy in Neoplastic and Non-Neoplastic Brain Disorders. Magnetic Resonance Imaging Clinics of North America, 6, 1-20.</mixed-citation></ref><ref id="scirp.51442-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Miller, B.L., Moats, R.A., Shonk, T., Ernst, T., Woolley, S. and Ross, B.D. (1993) Alzheimer Disease: Depiction of Increased Cerebral Myo-Inositol with Proton MR Spectroscopy. Radiology, 187, 433-437. 
http://dx.doi.org/10.1148/radiology.187.2.8475286</mixed-citation></ref><ref id="scirp.51442-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ernst, T., Chang, L., Melchor, R. and Mehringer, C.M. (1997) Frontotemporal Dementia and Early Alzheimer Disease: Differentiation with Frontal Lobe H-1 MR Spectroscopy. Radiology, 203, 829-836. 
http://dx.doi.org/10.1148/radiology.203.3.9169712</mixed-citation></ref><ref id="scirp.51442-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Terek, D., Koroglu, O.A., Gunes, S., Yalaz, M., Akisu, M., U?ar, S.K., Gokben, S., Coker, M. and Kultursay, N. (2012) Diagnostic Tools of Metabolic and Structural Brain Disturbances in Neonatal Non-Ketotic Hyperglycinemia. Pediatrics International, 54, 717-720. http://dx.doi.org/10.1111/j.1442-200X.2012.03591.x </mixed-citation></ref><ref id="scirp.51442-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Wozniak, J.R. and Lim, K.O. (2006) Advances in White Matter Imaging: A Review of in Vivo Magnetic Resonance Methodologies and Their Applicability to the Study of Development and Aging. Neuroscience &amp; Biobehavioral Reviews, 30, 762-774. http://dx.doi.org/10.1016/j.neubiorev.2006.06.003</mixed-citation></ref><ref id="scirp.51442-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Córdoba, J., Sanpedro, F., Alonso, J. and Rovira, A. (2002) 1H Magnetic Resonance in the Study of Hepatic Encephalopathy in Humans. Metabolic Brain Disease, 17, 415-429. http://dx.doi.org/10.1023/A:1021926405944</mixed-citation></ref><ref id="scirp.51442-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Novotny, E.J., Fulbright, R.K., Pearl, P.L., Gibson, K.M. and Rothman, D.L. (2003) Magnetic Resonance Spectroscopy of Neurotransmitters in Human Brain. Annals of Neurology, 54, 25-31. http://dx.doi.org/10.1002/ana.10697</mixed-citation></ref><ref id="scirp.51442-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">O’Gorman, R.L., Michels, L., Edden, R.A., Murdoch, J.B. and Martin, E. (2011) In Vivo Detection of GABA and Glutamate with MEGA-PRESS: Reproducibility and Gender Effect. Journal of Magnetic Resonance Imaging, 33, 1262-1267. http://dx.doi.org/10.1002/jmri.22520</mixed-citation></ref><ref id="scirp.51442-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Lazovic, J., Soto, H., Piccioni, D., Ru, J.R.L., Li, S., Mirsadraei, L. and Pop, B.W. (2012) Detection of 2-Hydroxyglutaric Acid in Vivo by Proton Magnetic Resonance Spectroscopy in U87 Glioma Cells Overexpressing Isocitrate Dehydrogenase-1 Mutation. Neuro-Oncology, 14, 1465-1472.</mixed-citation></ref><ref id="scirp.51442-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Elkhaled, A., Jalbert, L.E., Phillips, J.J., Yoshihara, H.A., Parvataneni, R., Srinivasan, R. and Nelson, S.J. (2012) Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas. Science Translational Medicine, 4, 116ra5.</mixed-citation></ref><ref id="scirp.51442-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Kaminogo, M., Ishimaru, H., Morikawa, M., Ochi, M., Ushijima, R., Tani, M. and Shibata, S. (2001) Diagnostic Potential of Short Echo Time MR Spectroscopy of Gliomas with Single-Voxel and Point-Resolved Spatially Localized Proton Spectroscopy of Brain. Neuroradiology, 43, 353-363. http://dx.doi.org/10.1007/s002340000473</mixed-citation></ref><ref id="scirp.51442-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Zand, D.J., Simon, E.M., Pulitzer, S.B., Wang, D.J., Wang, Z.J., Rorke, L.B., Palmieri, M. and Berry, G.T. (2003) In Vivo Pyruvate Detected by MR Spectroscopy in Neonatal Pyruvate Dehydrogenase Deficiency. American Journal of Neuroradiology, 24, 1471-1474.</mixed-citation></ref><ref id="scirp.51442-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Rae, C.D. (2014) A Guide to the Metabolic Pathways and Function of Metabolites Observed in Human Brain 1H Magnetic Resonance Spectra. Neurochemical Research, 39, 1-36. http://dx.doi.org/10.1007/s11064-013-1199-5</mixed-citation></ref><ref id="scirp.51442-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Panigrahy, A. and Blüml, S. (2009) Neuroimaging of Pediatric Brain Tumors: From Basic to Advanced Magnetic Resonance Imaging. Child Neurology, 24, 1343-1365. http://dx.doi.org/10.1177/0883073809342129</mixed-citation></ref><ref id="scirp.51442-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Blüml, S., Panigrahy, A., Laskov, M., Dhall, G., Krieger, M.D., Nelson, M.D. and Gilles, F.H. (2011) Elevated Citrate in Pediatric Astrocytomas with Malignant Progression. Neuro-Oncology, 13, 1107-1117.  
http://dx.doi.org/10.1093/neuonc/nor087</mixed-citation></ref><ref id="scirp.51442-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Mohammad, F.F., Hasan, D.I. and Ammar, M.G. (2014) MR Spectroscopy and Diffusion MR Imaging in Characterisation of Common Sellar and Supra-Sellar Neoplastic Lesions. The Egyptian Journal of Radiology and Nuclear Medicine, 45, 859-867. http://dx.doi.org/10.1016/j.ejrnm.2014.04.012</mixed-citation></ref><ref id="scirp.51442-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Yue, Q., Isobe, T., Shibata, Y., Anno, I., Kawamura, H., Yamamoto, Y. and Matsumura, A. (2008) New Observations Concerning the Interpretation of Magnetic Resonance Spectroscopy of Meningioma. European Radiology, 18, 2901-2911. http://dx.doi.org/10.1007/s00330-008-1079-6</mixed-citation></ref><ref id="scirp.51442-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Castillo, M., Kwock, L. and Mukherji, S.K. (1996) Clinical Applications of Proton MR Spectroscopy. American Journal of Neuroradiology, 17, 1-15.</mixed-citation></ref><ref id="scirp.51442-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Gillard, J.H., Waldman, A.D. and Barker, P.B. (2005) Clinical MR Neuroimaging. Cambridge University Press, New York.</mixed-citation></ref><ref id="scirp.51442-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Luthra, G., Parihar, A., Nath, K., Jaiswal, S., Prasad, K.N., Husain, N. and Gupta, R.K. (2007) Comparative Evaluation of Fungal, Tubercular, and Pyogenic Brain Abscesses with Conventional and Diffusion MR Imaging and Proton MR Spectroscopy. American Journal of Neuroradiology, 28, 1332-1338. http://dx.doi.org/10.3174/ajnr.A0548</mixed-citation></ref><ref id="scirp.51442-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Cecil, K.M. and Lenkinski, R.E. (1998) Proton MR Spectroscopy in Inflammatory and Infectious Brain Disorders. Neuroimaging Clinics of North America, 8, 863-880.</mixed-citation></ref><ref id="scirp.51442-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Lai, P.H., Li, K.T., Hsu, S.S., Hsiao, C.C., Yip, C.W., Ding, S. and Pan, H.B. (2005) Pyogenic Brain Abscess: Findings from in Vivo 1.5-T and 11.7-T in Vitro Proton MR Spectroscopy. American Journal of Neuroradiology, 26, 279-288.</mixed-citation></ref><ref id="scirp.51442-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Narayana, P.A. (2005) Magnetic Resonance Spectroscopy in the Monitoring of Multiple Sclerosis. Journal of Neuroimaging, 15, 46-57. http://dx.doi.org/10.1177/1051228405284200</mixed-citation></ref><ref id="scirp.51442-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Narayana, P.A., Doyle, T.J., Lai, D. and Wolinsky, J.S. (1998) Serial Proton Magnetic Resonance Spectroscopic Imaging, Contrast-Enhanced Magnetic Resonance Imaging, and Quantitative Lesion Volumetry in Multiple Sclerosis. Annals of Neurology, 43, 56-57. http://dx.doi.org/10.1002/ana.410430112</mixed-citation></ref><ref id="scirp.51442-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Savranlar, A., Ozer, T., Aydemir, S., Alkan, A. and Borazan, A. (2005) Proton Magnetic Resonance Spectroscopy Findings of Wilson’s Disease Case Report. Journal of Neurological Sciences (Turkish), 22, 297-303.</mixed-citation></ref><ref id="scirp.51442-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Saksena, S., Rai, V., Saraswat, V.A., Rathore, R.S., Purwar, A., Kumar, M. and Gupta, R.K. (2008) Cerebral Diffusion Tensor Imaging and in Vivo Proton Magnetic Resonance Spectroscopy in Patients with Fulminant Hepatic Failure. Journal of Gastroenterology and Hepatology, 23, 111-119. http://dx.doi.org/10.1111/j.1440-1746.2007.05158.x</mixed-citation></ref><ref id="scirp.51442-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Brand, A., Richter-Landsberg, C. and Leibfritz, D. (1993) Multinuclear NMR Studies on the Energy Metabolism of Glial and Neuronal Cells. Developmental Neuroscience, 15, 289-298. http://dx.doi.org/10.1159/000111347</mixed-citation></ref><ref id="scirp.51442-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Stafstrom, C.E. (2004) Dietary Approaches to Epilepsy Treatment: Old and New Options on the Men. Epilepsy Currents, 4, 215-222. http://dx.doi.org/10.1111/j.1535-7597.2004.46001.x</mixed-citation></ref><ref id="scirp.51442-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Rock, J.P., Hearshen, D., Scarpace, L., Croteau, D., Gutierrez, J., Fisher, J.L. and Mikkelsen, T. (2002) Correlations between Magnetic Resonance Spectroscopy and Image-Guided Histopathology, with Special Attention to Radiation Necrosis. Neurosurgery, 51, 912-920.</mixed-citation></ref><ref id="scirp.51442-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Davanzo, P., Thomas, M.A., Yue, K., Oshiro, T., Belin, T., Strober, M. and McCracken, J. (2001) Decreased Anterior Cingulate Myo-Inositol/Creatine Spectroscopy Resonance with Lithium Treatment in Children with Bipolar Disorder. Neuropsychopharmacology, 24, 359-369. http://dx.doi.org/10.1016/S0893-133X(00)00207-4</mixed-citation></ref><ref id="scirp.51442-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Kleihues, P. and Cavenee, W.K. (2000) Pathology and Genetics of Tumours of the Nervous System. International Agency for Research on Cancer, Lyon.</mixed-citation></ref><ref id="scirp.51442-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Chinn, R.J., Wilkinson, I.D., Hall-Craggs, M.A., Paley, M.N., Miller, R.F., Kendall, B.E. and Harrison, M.J. (1995) Toxoplasmosis and Primary Central Nervous System Lymphoma in HIV Infection: Diagnosis with MR Spectroscopy. Radiology, 197, 649-654. http://dx.doi.org/10.1148/radiology.197.3.7480733</mixed-citation></ref><ref id="scirp.51442-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Schultz Jr., K.D., Petronio, J., Narad, C. and Hunter, S.B. (1997) Solitary Intracerebral Juvenile Xanthogranuloma. Pediatric Neurosurgery, 26, 315-321. http://dx.doi.org/10.1159/000121212</mixed-citation></ref><ref id="scirp.51442-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Howe, F.A., Barton, S.J., Cudlip, S.A., Stubbs, M., Saunders, D.E., Murphy, M. and Griffiths, J.R. (2003) Metabolic Profiles of Human Brain Tumors Using Quantitative in Vivo 1H Magnetic Resonance Spectroscopy. Magnetic Resonance in Medicine, 49, 223-232. http://dx.doi.org/10.1002/mrm.10367</mixed-citation></ref><ref id="scirp.51442-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Furuya, S., Naruse, S., Ide, M., Morishita, H.E., Kizu, O., Ueda, S. and Maeda, T. (1997) Evaluation of Metabolic Heterogeneity in Brain Tumors Using 1H-Chemical Shift Imaging Method. NMR in Biomedicine, 10, 25-30. 
http://dx.doi.org/10.1002/(SICI)1099-1492(199701)10:1&lt;25::AID-NBM445&gt;3.0.CO;2-M</mixed-citation></ref></ref-list></back></article>